Regeneron's Pipeline Performance Positions Shares for Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy REGN?
Source: NASDAQ.COM
- Sales Growth: Regeneron's leading drug, Dupixent, generated $17.8 billion in revenue in 2025 and received its ninth approved indication, demonstrating strong market performance that is expected to further drive overall revenue growth for the company.
- Promising New Drug: The GLP-1 diabetes and weight loss drug olatorepatide has shown efficacy similar to leading market drugs in clinical trials, and if approved by the FDA, it could deliver $14.8 billion in annual revenues by 2028, significantly enhancing the company's market position.
- FDA Approval Expectations: The company anticipates at least four FDA approvals in 2023, a positive signal that not only boosts investor confidence but also lays the groundwork for future revenue growth, particularly with the rare disease treatment garetosmab.
- Expansive Market Outlook: Reports indicate that the weight loss drug market is expected to reach $23.6 billion by 2030, and with the potential of its new drugs, Regeneron is well-positioned to capture a significant share of this rapidly growing market, providing substantial returns for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 737.710
Low
637.00
Averages
808.50
High
1057
Current: 737.710
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Accelerates Biosimilar Drug Development and Approves New Treatments
- Accelerated Biosimilar Development: On March 9, 2026, the FDA recommended streamlining unnecessary clinical pharmacokinetic studies when scientifically justified, aiming to expedite biosimilar drug development and improve medicine affordability, thereby enhancing market competitiveness.
- Alternative to Animal Testing: The FDA released draft guidance on March 18, 2026, to assist drug developers in validating new approach methodologies as alternatives to animal testing, reflecting its commitment to scientific rigor and humane practices, which could reshape drug development standards.
- New Therapy Approval: On March 10, 2026, the FDA approved Wellcovorin as the first treatment for cerebral folate deficiency, a rare neurological condition, marking a significant advancement in neuroscience and potentially offering new hope for patients.
- Gene Therapy Innovation: The FDA approved Rocket Pharma's Kresladi on March 26, 2026, as the first gene therapy for Severe Leukocyte Adhesion Deficiency Type I, showcasing the potential of gene therapy in treating rare diseases and possibly driving stock price increases for related biotech companies.
See More
AstraZeneca's Lung Disease Drug Meets Trial Targets
- Successful Trials: AstraZeneca's experimental drug tozorakimab met its targets in two late-stage clinical trials, significantly reducing flare-ups in chronic obstructive pulmonary disease (COPD) patients, leading to a nearly 5% increase in the company's stock price.
- Massive Market Potential: With approximately 400 million people diagnosed with COPD globally, AstraZeneca forecasts peak annual sales for tozorakimab between $3 billion and $5 billion, far exceeding the pre-trial market estimate of $1 billion, highlighting its substantial commercial potential.
- Scientific Breakthrough: The trial results represent the first successful confirmatory Phase III trials for an IL-33 biologic, with AstraZeneca's executive vice president noting the significant scientific implications for COPD treatment strategies.
- Future Development Plans: AstraZeneca aims to launch over 20 new drugs in the next five years and has set a target of achieving $80 billion in annual sales by 2030, demonstrating its ambitious vision in the biopharmaceutical sector.
See More
Regeneron Faces Challenges but Shows Potential for Recovery
- Patent Expiration Impact: Regeneron's Eylea drug losing patent exclusivity has led to revenue pressures, yet the company's long-term returns remain solid, indicating market confidence in its future prospects.
- Sales Growth of Key Products: Dupixent, Regeneron's flagship product, is expected to continue growing through the early 2030s, particularly in treating conditions like wet age-related macular degeneration, which will help boost company revenues.
- Advancements in Drug Development: Regeneron is working on a gene therapy for genetic hearing loss, which could launch in the coming years if clinical trial data is favorable, further enriching its product portfolio and driving sales growth.
- Weight Loss Market Strategy: The company is developing two new products in the weight loss sector, with one candidate showing promising results in a phase 3 study in China, potentially positioning Regeneron as a notable player in the rapidly expanding weight loss market.
See More
Regeneron's Five-Year Outlook Amid Recovery
- Patent Expiration Impact: Regeneron's Eylea lost patent exclusivity, and while the stock has risen 35% recently, its long-term performance remains constrained, highlighting the company's challenges in navigating patent cliffs.
- Dupixent Sales Growth: As Regeneron's most important product, Dupixent is expected to continue growing through 2030, particularly in treating conditions like wet age-related macular degeneration, thereby enhancing the company's market position.
- New Drug Development Progress: Regeneron is working on a gene therapy for genetic hearing loss, which could launch in the coming years if clinical trial data is favorable, further enriching its product portfolio and driving sales growth.
- Weight Loss Drug Market Potential: The company is making strides in the weight loss drug market with two new products, particularly a GLP-1 medicine that performed well in a phase 3 study in China, potentially positioning Regeneron as a notable player in this rapidly growing sector.
See More
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
- New Indication Approval: The Ministry of Health, Labour and Welfare in Japan has approved Dupixent (dupilumab) for the treatment of moderate-to-severe bullous pemphigoid, marking the seventh approved indication for the drug in Japan and reinforcing its market position in dermatology.
- Clinical Trial Support: This approval is based on data from the LIBERTY-BP-ADEPT Phase 2/3 trial, demonstrating Dupixent's efficacy in improving patient symptoms, providing a strong scientific basis for its promotion in Japan.
- Market Reaction: Following this announcement, Sanofi's shares fell by 1.23% to €76.83, reflecting market caution regarding the new drug approval, which may impact short-term shareholder confidence.
- Strategic Implications: The multiple indications for Dupixent not only enhance Sanofi's competitiveness in immunotherapy but also have the potential to drive sales growth in the Japanese market, further expanding the company's influence in the global biopharmaceutical landscape.
See More
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
- Approval in Japan: Dupixent (dupilumab) has been granted marketing authorization by Japan's Ministry of Health, Labour and Welfare as the first targeted therapy for adults with moderate-to-severe bullous pemphigoid (BP), marking a significant advancement in the dermatology sector.
- Clinical Trial Results: In the LIBERTY-BP-ADEPT study, 18% of Dupixent patients achieved sustained remission at Week 36, compared to only 4% in the placebo group (p=0.0250), demonstrating its superior efficacy in treating BP.
- Safety Data: Among Dupixent patients, 26% reported treatment-related adverse events, with conjunctivitis being the most common at 4%, indicating a need for ongoing monitoring of the risk-benefit profile.
- Market Potential: This approval represents the seventh indication for Dupixent in Japan, which is expected to further enhance its acceptance in over 60 countries globally, strengthening the company's competitive position in the immunotherapy market.
See More
FDA Accelerates Biosimilar Drug Development and Approves New Treatments
- Accelerated Biosimilar Development: On March 9, 2026, the FDA recommended streamlining unnecessary clinical pharmacokinetic studies when scientifically justified, aiming to expedite biosimilar drug development and improve medicine affordability, thereby enhancing market competitiveness.
- Alternative to Animal Testing: The FDA released draft guidance on March 18, 2026, to assist drug developers in validating new approach methodologies as alternatives to animal testing, reflecting its commitment to scientific rigor and humane practices, which could reshape drug development standards.
- New Therapy Approval: On March 10, 2026, the FDA approved Wellcovorin as the first treatment for cerebral folate deficiency, a rare neurological condition, marking a significant advancement in neuroscience and potentially offering new hope for patients.
- Gene Therapy Innovation: The FDA approved Rocket Pharma's Kresladi on March 26, 2026, as the first gene therapy for Severe Leukocyte Adhesion Deficiency Type I, showcasing the potential of gene therapy in treating rare diseases and possibly driving stock price increases for related biotech companies.
See More
AstraZeneca's Lung Disease Drug Meets Trial Targets
- Successful Trials: AstraZeneca's experimental drug tozorakimab met its targets in two late-stage clinical trials, significantly reducing flare-ups in chronic obstructive pulmonary disease (COPD) patients, leading to a nearly 5% increase in the company's stock price.
- Massive Market Potential: With approximately 400 million people diagnosed with COPD globally, AstraZeneca forecasts peak annual sales for tozorakimab between $3 billion and $5 billion, far exceeding the pre-trial market estimate of $1 billion, highlighting its substantial commercial potential.
- Scientific Breakthrough: The trial results represent the first successful confirmatory Phase III trials for an IL-33 biologic, with AstraZeneca's executive vice president noting the significant scientific implications for COPD treatment strategies.
- Future Development Plans: AstraZeneca aims to launch over 20 new drugs in the next five years and has set a target of achieving $80 billion in annual sales by 2030, demonstrating its ambitious vision in the biopharmaceutical sector.
See More
Regeneron Faces Challenges but Shows Potential for Recovery
- Patent Expiration Impact: Regeneron's Eylea drug losing patent exclusivity has led to revenue pressures, yet the company's long-term returns remain solid, indicating market confidence in its future prospects.
- Sales Growth of Key Products: Dupixent, Regeneron's flagship product, is expected to continue growing through the early 2030s, particularly in treating conditions like wet age-related macular degeneration, which will help boost company revenues.
- Advancements in Drug Development: Regeneron is working on a gene therapy for genetic hearing loss, which could launch in the coming years if clinical trial data is favorable, further enriching its product portfolio and driving sales growth.
- Weight Loss Market Strategy: The company is developing two new products in the weight loss sector, with one candidate showing promising results in a phase 3 study in China, potentially positioning Regeneron as a notable player in the rapidly expanding weight loss market.
See More
Regeneron's Five-Year Outlook Amid Recovery
- Patent Expiration Impact: Regeneron's Eylea lost patent exclusivity, and while the stock has risen 35% recently, its long-term performance remains constrained, highlighting the company's challenges in navigating patent cliffs.
- Dupixent Sales Growth: As Regeneron's most important product, Dupixent is expected to continue growing through 2030, particularly in treating conditions like wet age-related macular degeneration, thereby enhancing the company's market position.
- New Drug Development Progress: Regeneron is working on a gene therapy for genetic hearing loss, which could launch in the coming years if clinical trial data is favorable, further enriching its product portfolio and driving sales growth.
- Weight Loss Drug Market Potential: The company is making strides in the weight loss drug market with two new products, particularly a GLP-1 medicine that performed well in a phase 3 study in China, potentially positioning Regeneron as a notable player in this rapidly growing sector.
See More
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
- New Indication Approval: The Ministry of Health, Labour and Welfare in Japan has approved Dupixent (dupilumab) for the treatment of moderate-to-severe bullous pemphigoid, marking the seventh approved indication for the drug in Japan and reinforcing its market position in dermatology.
- Clinical Trial Support: This approval is based on data from the LIBERTY-BP-ADEPT Phase 2/3 trial, demonstrating Dupixent's efficacy in improving patient symptoms, providing a strong scientific basis for its promotion in Japan.
- Market Reaction: Following this announcement, Sanofi's shares fell by 1.23% to €76.83, reflecting market caution regarding the new drug approval, which may impact short-term shareholder confidence.
- Strategic Implications: The multiple indications for Dupixent not only enhance Sanofi's competitiveness in immunotherapy but also have the potential to drive sales growth in the Japanese market, further expanding the company's influence in the global biopharmaceutical landscape.
See More
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
- Approval in Japan: Dupixent (dupilumab) has been granted marketing authorization by Japan's Ministry of Health, Labour and Welfare as the first targeted therapy for adults with moderate-to-severe bullous pemphigoid (BP), marking a significant advancement in the dermatology sector.
- Clinical Trial Results: In the LIBERTY-BP-ADEPT study, 18% of Dupixent patients achieved sustained remission at Week 36, compared to only 4% in the placebo group (p=0.0250), demonstrating its superior efficacy in treating BP.
- Safety Data: Among Dupixent patients, 26% reported treatment-related adverse events, with conjunctivitis being the most common at 4%, indicating a need for ongoing monitoring of the risk-benefit profile.
- Market Potential: This approval represents the seventh indication for Dupixent in Japan, which is expected to further enhance its acceptance in over 60 countries globally, strengthening the company's competitive position in the immunotherapy market.
See More
